Federal Circuit Affirms Invalidity of Ravgen Genetic Testing Patent in Streck Appeal
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Streck, Inc. v. Ravgen, Inc. |
| Case Number | 23-1989 (Fed. Cir.) |
| Court | Federal Circuit, Appeal from PTAB |
| Duration | June 2023 – Jan 2025 1 year 7 months |
| Outcome | Defendant Win – Patent Invalidated |
| Patent at Issue | |
| Accused Products | Methods for genetic disorder detection, including NIPT |
Case Overview
The Parties
⚖️ Appellant
Nebraska-based life sciences company known for hematology controls, stabilization reagents, and clinical laboratory products. Active in cell-free DNA and specimen preservation IP.
🛡️ Appellee
Maryland-based biotechnology company that has aggressively enforced a portfolio of patents directed to prenatal genetic testing and cell-free fetal DNA analysis.
The Patent at Issue
The patent central to this dispute is **U.S. Patent No. 7,332,277 B2** (Application No. US10/661165), assigned to Ravgen. This patent covers methods for detection of genetic disorders, a technology area encompassing non-invasive prenatal testing (NIPT) techniques that analyze cell-free DNA from maternal blood samples.
- • US 7,332,277 B2 — Methods for detection of genetic disorders
Developing a genetic diagnostic product?
Check if your technology might be impacted by similar rulings or related patents.
The Verdict & Legal Analysis
Outcome
The Federal Circuit issued a clear disposition: AFFIRMED. The court upheld the lower tribunal’s finding that the claims of U.S. Patent No. 7,332,277 B2 are unpatentable. No damages award or injunctive relief is implicated given the invalidity outcome.
Verdict Cause Analysis
The verdict cause is classified as Patentability — Invalidity/Cancellation Action, with the base of termination recorded as Unpatentable. This indicates the Federal Circuit affirmed a finding that the asserted claims of the ‘277 patent failed to satisfy one or more patentability requirements under 35 U.S.C. §§ 102 (novelty), 103 (obviousness), or related statutory provisions.
Legal Significance
- Ravgen’s portfolio enforcement strategy faces headwinds. Federal Circuit affirmance of invalidity for a core portfolio patent weakens leverage in ongoing and future licensing negotiations.
- CAFC scrutiny of diagnostic method patents continues. Post-*Alice* and *Mayo* jurisprudence has created sustained pressure on method-of-detection patents, and affirmances of invalidity reinforce that claim scope must be carefully calibrated.
- Appeal-stage invalidity affirmances are difficult to overcome. Parties holding similar genetic diagnostic patents should treat this outcome as a signal to audit claim strength proactively.
Strategic Takeaways
- For Patent Holders: Broad method claims in genetic diagnostics must be anchored to specific, well-supported technical embodiments. Prosecution strategies should emphasize narrow, defensible dependent claims alongside broader independent claims.
- For Accused Infringers: IPR petitions and invalidity challenges at PTAB remain powerful tools against aggressive patent assertion in the diagnostics space. A successful PTAB outcome, confirmed by the Federal Circuit, extinguishes the patent entirely.
- For R&D Teams: Freedom-to-operate (FTO) analyses should be updated in light of this ruling. With U.S. Patent No. 7,332,277 B2 now unpatentable, product development teams previously concerned about Ravgen’s claims in this patent may have reduced exposure.
Filing a genetic diagnostic patent?
Learn from this case. Use AI to draft stronger claims that can withstand invalidity challenges.
Power Your Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in genetic diagnostic methods. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related genetic diagnostic patents
- See which companies are most active in this space
- Understand claim invalidity patterns
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Diagnostic method claims on cell-free DNA
Related Patents
Multiple patents in Ravgen’s portfolio
Claim Invalidity Precedent
Influences future diagnostic patent challenges
✅ Key Takeaways
For Patent Attorneys & Litigators
Federal Circuit affirms unpatentability of Ravgen’s US7332277B2 genetic disorder detection patent in Streck v. Ravgen, Case No. 23-1989.
Search related case law →Invalidity/cancellation actions at PTAB, confirmed on appeal, deliver complete patent extinguishment — a strategically superior outcome to non-infringement alone.
Explore PTAB insights →Method-of-detection patents in genomics remain high-risk for invalidity challenges; claim drafting must anticipate obviousness attacks over prior art diagnostic literature.
Try AI patent drafting →Marshall Gerstein & Borun and Desmarais LLP represent formidable competing counsel models for future case team assembly in this space.
View legal teams’ portfolios →For IP Professionals
Audit genetic diagnostic patent portfolios for claim vulnerability consistent with grounds that invalidated the ‘277 patent.
Run portfolio analysis →Reassess licensing positions involving Ravgen’s portfolio in light of this and related invalidity rulings.
Explore licensing intelligence →Track continuation and related patents to identify remaining enforcement risk.
Monitor patent families →For R&D Teams
Update FTO analyses referencing US7332277B2 — the patent is unpatentable and no longer an infringement risk.
Start FTO analysis for my product →Maintain awareness of Ravgen’s broader patent portfolio before concluding clearance in the genetic disorder detection space.
View related patents →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.